A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...
TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...
About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...
Nutrition is the foundation, that’s what Dr. John Lewis says in this week’s Medical Monday.
Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...
Chennai: At 25, Bhanupriya was just another TNPSC aspirant from Madurai, preparing for her exams. One day, she lost partial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results